Clinical Trials · NCT00064714
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 47
- Start date
- Jul 2003
- Locations
- 1 site, United States
- Primary endpoint
- Change in basal C-peptide level